Alyeska Investment Group’s Aerie Pharmaceuticals, Inc. AERI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-100,000
| Closed | -$750K | – | 667 |
|
|
2022
Q2 | $750K | Hold |
100,000
| – | – | 0.01% | 508 |
|
|
2022
Q1 | $910K | Buy |
+100,000
| New | +$910K | 0.01% | 526 |
|
|
2021
Q1 | – | Sell |
-206,551
| Closed | -$2.79M | – | 862 |
|
|
2020
Q4 | $2.79M | Sell |
206,551
-1,652
| -0.8% | -$22.3K | 0.04% | 340 |
|
|
2020
Q3 | $2.45M | Hold |
208,203
| – | – | 0.04% | 326 |
|
|
2020
Q2 | $3.07M | Sell |
208,203
-29,270
| -12% | -$432K | 0.05% | 311 |
|
|
2020
Q1 | $3.21M | Buy |
237,473
+70,946
| +43% | +$958K | 0.06% | 223 |
|
|
2019
Q4 | $4.03M | Buy |
166,527
+632
| +0.4% | +$15.3K | 0.05% | 235 |
|
|
2019
Q3 | $3.19M | Buy |
165,895
+42,994
| +35% | +$826K | 0.05% | 248 |
|
|
2019
Q2 | $3.63M | Buy |
+122,901
| New | +$3.63M | 0.05% | 253 |
|
|
2019
Q1 | – | Sell |
-98,000
| Closed | -$3.54M | – | 435 |
|
|
2018
Q4 | $3.54M | Buy |
+98,000
| New | +$3.54M | 0.05% | 233 |
|
|
2018
Q3 | – | Sell |
-84,288
| Closed | -$5.69M | – | 513 |
|
|
2018
Q2 | $5.69M | Sell |
84,288
-216,815
| -72% | -$14.6M | 0.05% | 251 |
|
|
2018
Q1 | $16.3M | Buy |
301,103
+164,976
| +121% | +$8.95M | 0.14% | 169 |
|
|
2017
Q4 | $8.13M | Sell |
136,127
-55,155
| -29% | -$3.3M | 0.06% | 214 |
|
|
2017
Q3 | $9.3M | Buy |
191,282
+131,282
| +219% | +$6.38M | 0.07% | 235 |
|
|
2017
Q2 | $3.15M | Buy |
60,000
+33,442
| +126% | +$1.76M | 0.03% | 295 |
|
|
2017
Q1 | $1.2M | Sell |
26,558
-78,070
| -75% | -$3.54M | 0.01% | 413 |
|
|
2016
Q4 | $3.96M | Sell |
104,628
-29,323
| -22% | -$1.11M | 0.03% | 337 |
|
|
2016
Q3 | $5.06M | Buy |
+133,951
| New | +$5.06M | 0.05% | 311 |
|
|
2014
Q4 | – | Sell |
-24,927
| Closed | -$516K | – | 520 |
|
|
2014
Q3 | $516K | Buy |
+24,927
| New | +$516K | 0.01% | 338 |
|
|
2014
Q1 | – | Sell |
-51,508
| Closed | -$925K | – | 356 |
|
|
2013
Q4 | $925K | Buy |
+51,508
| New | +$925K | 0.04% | 231 |
|